

ASX Announcement

Racura Oncology Investor Briefings Perth & Auckland

16 June 2026

Racura Oncology Limited (“Racura”) wishes to invite interested investors to attend investor briefings in Perth (Western Australia) on 26 June 2026, and Auckland (New Zealand) on 5 August 2026.

Perth Briefing

Managing Director and Chief Executive Officer, Dr Daniel Tillett, will host a morning tea and briefing, where investors will have the opportunity to hear the latest company updates and to ask questions.

Date	Friday, 26 June 2026
Time	10:15AM for a 10:30AM start
Location	Royal Freshwater Bay Yacht Club Keane's Point, 1 Hobbs Place Peppermint Grove 6011, Perth, WA
RSVP	Places are strictly limited so please RSVP by Monday 22 June 2026 via: racura@irdepartment.com.au

Please include ‘Perth Briefing’ in your email subject and advise of any dietary requirements.

Auckland Briefing

Executive Chair, Dr Pete Smith, will host a morning tea and briefing, where investors will have the opportunity to hear the latest company updates and to ask questions.

Date	Wednesday, 5 August 2026
Time	10:15AM for a 10:30AM start
Location	To be confirmed (central CBD location)
RSVP	To enable appropriate venue selection please RSVP by Friday 3 July 2026 via: racura@irdepartment.com.au

Please include ‘Auckland Briefing’ in your email subject and advise of any dietary requirements.

-ENDS-

About Racura Oncology

Racura Oncology (ASX: RAC) is a Phase 3 clinical-stage biopharmaceutical company with a mission to silence cancer.

Racura's lead asset, (E,E)-bisantrene, is a small molecule anticancer agent that primarily functions via G4-DNA & RNA binding, leading to potent silencing of the important cancer growth regulator MYC. (E,E)-bisantrene has demonstrated therapeutic activity in cancer patients with a well-characterised safety profile. Recent discoveries made by Racura have enabled composition of matter IP filings that provides for 20 years of patent protection over (E,E)-bisantrene.

Racura is advancing a proprietary formulation of (E,E)-bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a Phase 3 clinical program in acute myeloid leukaemia (AML), a Phase 1a/b program in mutant epidermal growth factor receptor non-small cell lung cancer (EGFRm NSCLC), and a Phase 1a/b program in combination with the anthracycline doxorubicin, where we aim to deliver both cardioprotection and enhanced anticancer activity for solid tumour patients.

Racura has collaborated with Astex, Emory University, Purdue University, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong, and University of Newcastle. Racura is actively exploring partnerships, licence agreements, or a commercial merger and acquisition to accelerate access to RC220 for patients with cancer across the world. Learn more at www.racuraoncology.com.

If you have any questions on this announcement, or any past Racura Oncology announcements, please visit our [Interactive Announcements](#) page.

Racura encourages all investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by

Daniel Tillett, CEO

info@racuraoncology.com

Media Contact

Cherie Hartley +61 418 737 020

cherie.hartley@irdepartment.com.au